Tag: inflammatory bowel disease treatment market size

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Inflammatory Bowel Disease Treatment Market Revenue Growth On Track For A 9.8% CAGR Through 2030

The inflammatory bowel disease treatment market has witnessed significant expansion in recent years. Its valuation is forecast to climb from $27.19 billion in 2025 to $29.8 billion in 2026, advancing at a compound annual growth rate (CAGR) of 9.6%. This historical growth can be linked to the increasing prevalence of ulcerative colitis and Crohn’s disease, enhanced awareness of available IBD treatment options, the broadening of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early embrace of biologics in more developed areas.

The inflammatory bowel disease treatment market is projected to experience robust expansion over the coming years. Its valuation is set to reach $43.36 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the projection period stems from heightened investment in precision medicine, the creation of innovative anti-inflammatory treatments, the incorporation of digital health platforms for monitoring patients, increased adoption of biologics and biosimilars, and expanded availability of ibd treatment in developing markets. Significant trends during the forecast period encompass the evolution of personalized ibd therapy, a rise in the application of biologics for treatment, the emergence of minimally invasive drug delivery methods, an increased emphasis on patient adherence initiatives, and the expansion of specialty pharmacies catering to ibd.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=88477813&type=smp&name=Inflammatory%20Bowel%20Disease%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Inflammatory Bowel Disease Treatment Market Growth Momentum: What Factors Are Shaping Demand?

The increasing incidence of Crohn’s disease and ulcerative colitis is a significant factor propelling the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are forms of inflammatory bowel diseases (IBD) that lead to inflammation and sores (ulcers) within the digestive tract. The growing number of Crohn’s disease and ulcerative colitis cases is anticipated to heighten the demand for inflammatory bowel disease treatments, as these are widely utilized to alleviate bowel inflammation and to lessen and prevent medical complications. For example, in November 2024, data from the Crohn’s & Colitis Foundation, a US-based Non-profit organization, revealed that approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, which includes both Crohn’s disease and ulcerative colitis. Among this young population, Crohn’s disease is more common, showing a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Thus, the escalating prevalence of Crohn’s disease and ulcerative colitis is expected to drive the growth of the inflammatory bowel disease treatment market.

Inflammatory Bowel Disease Treatment Market Segment Trends And Revenue Contributors

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Inflammatory Bowel Disease Treatment Market Trends Redefining Industry Growth

Companies within the inflammatory bowel disease treatment market are innovating new products, including therapies for moderate to severe active ulcerative colitis, aiming to expand their customer reach, boost sales, and generate higher revenue. These treatments for moderate to severe active ulcerative colitis generally involve pharmaceuticals and, in some cases, surgical procedures. As an example, in October 2023, the US-based pharmaceutical firm, Eli Lilly and Company, disclosed that the U. S. Food and Drug Administration (FDA) had approved Omvoh (mirikizumab-mrkz). This product, offered as both an infusion (300 mg/15 mL) and an injection (100 mg/mL), stands as the first and only interleukin-23p19 (IL-23p19) antagonist developed to address moderately to severely active ulcerative colitis (UC) in adults. Omvoh is engineered to target the p19 subunit of IL-23, thereby inhibiting the IL-23 pathway, which is a key driver of the inflammation central to UC’s progression. The therapeutic approach for Omvoh commences with three 300-mg IV infusions, given once a week every four weeks, followed by a maintenance stage consisting of two 100-mg subcutaneous self-injections administered every four weeks.

Inflammatory Bowel Disease Treatment Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

View The Full Inflammatory Bowel Disease Treatment Market Report:

https://thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Inflammatory Bowel Disease Treatment Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Inflammatory Bowel Disease Treatment Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for treating inflammatory bowel disease has experienced robust expansion in recent years. Its valuation is projected to rise from $27.19 billion in 2025 to $29.8 billion in 2026, representing a compound annual growth rate (CAGR) of 9.6%. Several factors contributed to this growth during the historic period, including a higher incidence of ulcerative colitis and Crohn’s disease, increased knowledge about available IBD therapies, the broadening of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early integration of biologic treatments in developed areas.

The inflammatory bowel disease treatment market is anticipated to experience robust expansion over the coming years. By 2030, it is projected to reach a valuation of $43.36 billion, reflecting a compound annual growth rate (CAGR) of 9.8%. This forecasted growth is driven by heightened investment in precision medicine, the emergence of novel anti-inflammatory therapies, the incorporation of digital health platforms for monitoring patients, increased uptake of biologics and biosimilars, and broader access to IBD care in developing markets. Key trends shaping this period include the advancement of personalized IBD treatments, a rising reliance on biologic therapies, the adoption of minimally invasive drug delivery methods, a greater emphasis on patient adherence initiatives, and the expansion of specialty pharmacies focused on IBD management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Inflammatory Bowel Disease Treatment Market Demand Drivers Creating New Revenue Opportunities

The increasing occurrence of Crohn’s disease and ulcerative colitis is a major factor propelling the inflammatory bowel disease treatment market forward. These two conditions, classified as forms of inflammatory bowel disease (IBD), trigger digestive tract inflammation and the formation of ulcers. As the number of individuals diagnosed with Crohn’s disease and ulcerative colitis rises, the need for effective treatments is anticipated to grow, given that these therapies are extensively employed to alleviate bowel inflammation and prevent further complications. A case in point is data from November 2024, released by the Crohn’s & Colitis Foundation, a US non-profit, which indicates that about 100,429 children and adolescents under the age of 20 in the United States are living with IBD, which includes both Crohn’s disease and ulcerative colitis. Within this pediatric group, Crohn’s disease shows a higher prevalence rate of 71 per 100,000, while ulcerative colitis stands at 44 per 100,000. Consequently, the growing prevalence of these conditions is set to fuel expansion of the inflammatory bowel disease treatment market.

Inflammatory Bowel Disease Treatment Market Segmentation: How Is The Market Structured Across Key Categories?

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Inflammatory Bowel Disease Treatment Market Trends Driving Strategic Industry Expansion

Key industry players in the market for inflammatory bowel disease therapies are introducing cutting-edge products, such as treatments for moderate to severe active ulcerative colitis, aimed at reaching broader audiences, boosting sales, and driving higher profits. Therapeutic approaches for moderate to severe active ulcerative colitis often incorporate pharmacological solutions and, in some cases, surgical procedures. As an example, in October 2023, Eli Lilly and Company, a pharmaceutical firm based in the United States, received clearance from the U.S. Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz), presented in both an infusion form (300 mg/15 mL) and an injectable version (100 mg/mL). This medication is the first and only interleukin-23p19 (IL-23p19) antagonist created to manage adults diagnosed with moderately to severely active ulcerative colitis (UC). Omvoh is precisely engineered to target the p19 subunit of IL-23, thereby inhibiting the IL-23 pathway, a key driver of inflammation that plays a major role in the onset of UC. The dosing schedule for Omvoh starts with three 300-mg intravenous infusions given once every four weeks, followed by a maintenance stage that consists of two 100-mg subcutaneous self-administered injections every four weeks.

Inflammatory Bowel Disease Treatment Market Competitive Landscape And Leading Companies

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

Access The Complete Inflammatory Bowel Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Inflammatory Bowel Disease Treatment Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Inflammatory Bowel Disease Treatment Market From 2026 To 2030?

The inflammatory bowel disease treatment market has seen significant expansion in recent years. This market is expected to grow from $27.19 billion in 2025 to $29.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, this growth can be attributed to an increased prevalence of ulcerative colitis and Crohn’s disease, greater awareness of available IBD treatment options, the expansion of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early adoption of biologics in advanced economies.

The inflammatory bowel disease treatment market is anticipated to show significant expansion in the coming years, reaching $43.36 billion in 2030 with a compound annual growth rate (CAGR) of 9.8%. This increase over the forecast period is driven by various factors, such as increased investment in precision medicine, the development of innovative anti-inflammatory therapies, the integration of digital health platforms for monitoring patients, a rise in the adoption of biologics and biosimilars, and the broader availability of IBD treatment in emerging markets. Noteworthy trends during this time include the advancement of personalized IBD therapy, the growing application of biologics in treatment, the development of minimally invasive drug delivery systems, an increased focus on programs for patient adherence, and the expansion of specialty pharmacies for IBD care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Influential Factors Are Boosting The Inflammatory Bowel Disease Treatment Market Demand?

The growing incidence of Crohn’s disease and ulcerative colitis is a significant driver for the inflammatory bowel disease treatment market. Both Crohn’s disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and sores in the digestive tract. The increasing number of cases of these conditions is expected to boost demand for inflammatory bowel disease treatments, as they are widely utilized to reduce bowel inflammation and lessen or prevent medical complications. For instance, in November 2024, according to the Crohn’s & Colitis Foundation, a US-based Non-profit organization, approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Among this pediatric population, Crohn’s disease is more common, with a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Hence, the rising prevalence of Crohn’s disease and ulcerative colitis is anticipated to drive the inflammatory bowel disease treatment market growth.

What Segment Types Are Included In The Inflammatory Bowel Disease Treatment Market Analysis?

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Which Trends Are Influencing The Direction Of The Inflammatory Bowel Disease Treatment Market?

Leading firms in the inflammatory bowel disease treatment sector are introducing novel products, including therapies for moderate to severe active ulcerative colitis, aiming to serve broader customer segments, boost sales, and enhance revenue. These treatments for moderate to severe active ulcerative colitis commonly involve pharmaceutical drugs and, on occasion, surgical procedures. As an example, in October 2023, US-based pharmaceutical company Eli Lilly and Company revealed that the U. S. Food and Drug Administration (FDA) had approved Omvoh (mirikizumab-mrkz). This product, available as both an infusion (300 mg/15 mL) and an injection (100 mg/mL), represents the first and only interleukin-23p19 (IL-23p19) antagonist developed for adults suffering from moderately to severely active ulcerative colitis (UC). Omvoh is engineered to target the p19 subunit of IL-23, thereby effectively inhibiting the IL-23 pathway, which plays a significant role in the inflammation leading to UC. The treatment protocol for Omvoh starts with three 300-mg IV infusions, given weekly for four weeks, followed by a maintenance stage consisting of two 100-mg subcutaneous self-injections every four weeks.

Who Are The Firms Contributing To The Inflammatory Bowel Disease Treatment Market Ecosystem?

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

Access The Complete Inflammatory Bowel Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Which Region Commands The Largest Share Of The Inflammatory Bowel Disease Treatment Market?

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Inflammatory Bowel Disease Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Crohns Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Inflammatory Bowel Disease Treatment Market Expected To Change From 2026 To 2030?

The inflammatory bowel disease treatment market size has experienced significant expansion in recent years. This market is expected to grow from $27.19 billion in 2025 to $29.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, the growth can be attributed to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, greater awareness of IBD treatment options, the expansion of hospital and retail pharmacy networks, the availability of generic aminosalicylates, and the early adoption of biologics in developed regions.

The market for inflammatory bowel disease treatments is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $43.36 billion, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected growth is driven by several factors, including heightened investment in precision medicine, the creation of innovative anti-inflammatory treatments, the incorporation of digital health platforms for monitoring patients, the rising adoption of biologics and biosimilars, and the broader availability of IBD treatment in developing economies. Key trends expected during this period involve the evolution of personalized IBD therapies, an increased reliance on biologics in treatment protocols, the emergence of minimally invasive drug delivery systems, a stronger emphasis on patient adherence initiatives, and the expansion of specialty pharmacies catering to IBD patients.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Key Factors Are Shaping The Inflammatory Bowel Disease Treatment Market Landscape?

The increasing occurrence of Crohn’s disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are forms of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tract. The escalating instances of Crohn’s disease and ulcerative colitis are anticipated to boost demand for inflammatory bowel disease treatments, as these therapies are widely employed to alleviate bowel inflammation and reduce and prevent medical complications. For instance, in November 2024, according to the Crohn’s & Colitis Foundation, a US-based Non-profit organization, approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Within this pediatric population, Crohn’s disease is more common, with a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Hence, the rising prevalence of Crohn’s disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment market growth.

What Segment Categories Shape The Inflammatory Bowel Disease Treatment Market Segment Landscape?

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Which Trends Are Impacting The Progress Of The Inflammatory Bowel Disease Treatment Market?

Leading companies in the inflammatory bowel disease treatment market are developing innovative products, such as therapies for moderate to severe active ulcerative colitis, to reach broader customer bases, increase sales, and boost revenue. Treatments for moderate to severe active ulcerative colitis typically involve medications and, at times, surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz). Available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, Omvoh stands as the first and only interleukin-23p19 (IL-23p19) antagonist specifically designed to treat adults with moderately to severely active ulcerative colitis (UC). This medication is precisely formulated to target the p19 subunit of IL-23, thereby effectively blocking the IL-23 pathway, which is known to cause the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen commences with three 300-mg IV infusions, administered once a week every four weeks, before transitioning to a maintenance phase that includes two 100-mg subcutaneous self-injections every four weeks.

Who Are The Companies Operating Across The Inflammatory Bowel Disease Treatment Market Value Chain?

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

Get The Full Inflammatory Bowel Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Which Region Leads The Inflammatory Bowel Disease Treatment Market In Terms Of Market Share?

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Inflammatory Bowel Disease Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Crohns Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Inflammatory Bowel Disease Treatment Market During The Forecast Period 2026–2030?

The inflammatory bowel disease treatment market size has experienced significant expansion over recent years. This market is projected to expand from $27.19 billion in 2025 to $29.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. The factors contributing to its historical growth include the increasing prevalence of ulcerative colitis and crohn’s disease, enhanced awareness regarding IBD treatment options, the broadening of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early integration of biologics in developed regions.

The market for inflammatory bowel disease treatments is set to experience significant expansion over the next few years, with projections indicating it will reach $43.36 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.8%. This anticipated growth throughout the forecast period can be attributed to increased funding in precision medicine, the development of new anti-inflammatory therapies, the integration of digital health platforms for patient monitoring, a rise in the adoption of biologics and biosimilars, and expanded access to IBD treatment in developing markets. Noteworthy trends during this period include the advancement of personalized IBD therapies, a growing reliance on biologics for treatment, the emergence of minimally invasive drug delivery systems, an elevated focus on patient adherence programs, and the proliferation of specialty pharmacies catering to IBD.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Drivers Are Expected To Influence The Inflammatory Bowel Disease Treatment Market During The Forecast Period?

The increasing occurrence of Crohn’s disease and ulcerative colitis is a major catalyst for the inflammatory bowel disease treatment market. These conditions are forms of inflammatory bowel diseases (IBD), characterized by inflammation and ulcers (sores) within the digestive system. The growing number of Crohn’s disease and ulcerative colitis cases is anticipated to heighten the need for inflammatory bowel disease treatments, given their extensive use in alleviating bowel inflammation and mitigating or avoiding health complications. For example, data from November 2024, provided by the Crohn’s & Colitis Foundation, a US-based Non-profit organization, indicates that around 100,429 children and adolescents in the United States, aged under 20, suffer from IBD, which includes both Crohn’s disease and ulcerative colitis. Within this younger demographic, Crohn’s disease is more prevalent, affecting 71 per 100,000 individuals, while ulcerative colitis stands at 44 per 100,000. Consequently, the expanding incidence of Crohn’s disease and ulcerative colitis is projected to fuel the growth of the inflammatory bowel disease treatment market.

What Market Segments Are Evaluated Within The Inflammatory Bowel Disease Treatment Market?

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

What Industry Trends Are Redefining The Inflammatory Bowel Disease Treatment Market?

Leading companies operating in the inflammatory bowel disease treatment market are developing innovative products, such as therapies for moderate to severe active ulcerative colitis, to reach broader customer bases, increase sales, and boost revenue. Treatments for moderate to severe active ulcerative colitis typically involve medications and sometimes surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz). Available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, it is the inaugural and sole interleukin-23p19 (IL-23p19) antagonist designed for adults with moderately to severely active ulcerative colitis (UC). Omvoh is specifically tailored to focus on the p19 subunit of IL-23, effectively blocking the IL-23 pathway, which is responsible for the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen begins with three 300-mg IV infusions, administered once a week every four weeks, and then shifts to a maintenance phase involving two 100-mg subcutaneous self-injections every four weeks.

Who Are The Top Market Participants Influencing The Inflammatory Bowel Disease Treatment Market?

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

Read the full inflammatory bowel disease treatment market report here:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Which Region Is Forecast To Lead The Inflammatory Bowel Disease Treatment Market In Terms Of Market Size?

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Inflammatory Bowel Disease Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp

Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Crohns Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the inflammatory bowel disease treatment market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Inflammatory Bowel Disease Treatment Market expected to reach by 2030?

The inflammatory bowel disease treatment market size has seen robust expansion in recent years. It is projected to increase from $27.19 billion in 2025 to $29.8 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. The market’s past growth can be attributed to factors such as the rising incidence of ulcerative colitis and Crohn’s disease, increased knowledge about IBD treatment alternatives, the expansion of hospital and retail pharmacy infrastructures, the availability of generic aminosalicylates, and the initial embrace of biologics in developed parts of the world.

The inflammatory bowel disease treatment market is projected to experience robust expansion in the coming years, anticipated to reach $43.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This anticipated expansion during the forecast period stems from factors such as enhanced investment in precision medicine, the creation of innovative anti-inflammatory treatments, the incorporation of digital health platforms for patient oversight, a rise in the uptake of biologics and biosimilars, and the broadening of ibd treatment availability in developing regions. Significant developments projected for this timeframe encompass the advancement of personalized ibd therapies, an escalating reliance on biologics in treatment protocols, the emergence of minimally invasive drug delivery methods, a heightened emphasis on patient compliance initiatives, and the proliferation of specialty pharmacies dedicated to ibd.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp

What Drivers Are Driving Adoption Within The Inflammatory Bowel Disease Treatment Market?

The increasing occurrence of Crohn’s disease and ulcerative colitis is a primary force propelling the inflammatory bowel disease treatment market. These conditions, Crohn’s disease and ulcerative colitis, are forms of inflammatory bowel diseases (IBD) that lead to inflammation and sores within the digestive tract. The growing number of cases involving Crohn’s disease and ulcerative colitis is projected to heighten the demand for inflammatory bowel disease treatments, as these are widely utilized to alleviate bowel inflammation and to minimize or prevent associated medical complications. For instance, data from November 2024, according to the Crohn’s & Colitis Foundation, a US-based Non-profit organization, indicates that approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Within this pediatric group, Crohn’s disease is more prevalent, showing a rate of 71 per 100,000, in contrast to 44 per 100,000 for ulcerative colitis. Consequently, the rising incidence of Crohn’s disease and ulcerative colitis is anticipated to drive the expansion of the inflammatory bowel disease treatment market.

What Segments Are Included Within The Inflammatory Bowel Disease Treatment Market?

The inflammatory bowel disease treatment market covered in this report is segmented –

1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes

2) By Type: Crohn’s Disease, Ulcerative Colitis

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide

2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol

4) By IL Inhibitors: Ustekinumab, Guselkumab

5) By Anti-Integrin: Vedolizumab, Natalizumab

6) By JAK Inhibitors: Tofacitinib, Filgotinib

7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies

Which Trends Are Expected To Influence The Inflammatory Bowel Disease Treatment Market In The Upcoming Years?

Major companies operating in the inflammatory bowel disease treatment market are developing advanced products, such as therapies for moderate to severe active ulcerative colitis, to cater to larger customer bases, increase sales, and boost revenue. Treatments for moderate to severe active ulcerative colitis typically include medications and sometimes surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), which is available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, marking it as the inaugural and sole interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh is specifically engineered to target the p19 subunit of IL-23, effectively blocking the IL-23 pathway, which is responsible for the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen initiates with three 300-mg IV infusions, administered once a week every four weeks, before transitioning to a maintenance phase involving two 100-mg subcutaneous self-injections every four weeks.

Who Are The Major Companies Operating In The Inflammatory Bowel Disease Treatment Market?

Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Inflammatory Bowel Disease Treatment Market?

North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Inflammatory Bowel Disease Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp

Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Crohns Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model